Weight loss outcomes can differ from person to person. In a 68-week clinical study involving 1,961 adults with obesity or excess weight and related health conditions, individuals using semaglutide lost about 35 pounds on average, which equals roughly 15% of their body weight. Those who received a placebo experienced an average reduction of around 6 pounds, or about 2.5%.
Participants in the study began at an average weight of approximately 232 pounds. Eligibility included adults with a BMI of 30 or higher, or 27 and above with conditions like high blood pressure or elevated cholesterol, while individuals with type 2 diabetes were not included. Alongside medication, all participants followed a lower-calorie diet and increased physical activity. Around 7% of those using semaglutide discontinued due to side effects, compared to 3.1% in the placebo group.
Study Reference: STEP 1 Trial — Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.